Bulletin
Investor Alert

Associated Press Archives | Email alerts

May 9, 2021, 12:30 p.m. EDT

Biden administration set to ramp up vaccine diplomacy in drive to inoculate world against COVID-19

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    BioNTech SE ADR (BNTX)
  • X
    BioNTech SE ADR (22UA)

or Cancel Already have a watchlist? Log In

Associated Press

WASHINGTON (AP) — It won’t speed the manufacture of vaccines. It enraged the developers who delivered lifesaving doses in record time. But President Joe Biden’s decision to support waiving intellectual property rights for coronavirus shots had a broader purpose: to broadcast his administration’s commitment to global leadership.

More than a month of internal debate led up to Biden’s decision this week to endorse international calls to strip patent protections for vaccines.

The policy shift, embraced by many charitable service organizations around the world and liberals at home, wasn’t new. Biden endorsed it during his campaign for the White House. But the idea was the subject of tense discussions inside the administration over how best to bring the pandemic to an end while restoring U.S. influence abroad.

Capitol Report: Biden’s move on vaccine patents represents blow for the second-biggest spender on Washington lobbying

In the best case, officials acknowledge it will take at least a year for any additional vaccines to be produced due to the change. Key European leaders are adamantly opposed to the waivers, and securing the required consensus at the World Trade Organization many never happen.

The specialized production, particularly of the cutting-edge mRNA vaccines made by Pfizer /zigman2/quotes/202877789/composite PFE +0.48% with German partner BioNTech /zigman2/quotes/214419716/composite BNTX +4.60% /zigman2/quotes/222361179/delayed XE:22UA +3.93% and Moderna /zigman2/quotes/205619834/composite MRNA +6.30% , would take even longer. Moreover, the matter could become less pressing if vaccine manufacturers can produce enough to satisfy international demand themselves.

To Biden, White House officials said, that’s largely beside the point, as officials cast the decision as indicative of the president’s efforts to return the U.S. to the position of leadership after four years of unilateralism and protectionism under the former president, Donald Trump.

“This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures,” U.S. Trade Representative Katherine Tai said Wednesday in announcing the move.

The announcement was met with surprise and disappointment by some of Biden’s closest European allies. German Chancellor Angela Merkel quickly weighed in against it, with a government spokesman saying it would cause “severe complications” for the production of vaccines.

The timing of the decision also blindsided the vaccine companies, which had aggressively discouraged the administration from making a choice they feel will hurt American producers.

Officials noted, however, that Tai held more than two dozen meetings with stakeholders, including the drug manufacturers.

Commerce Secretary Gina Raimondo also opposed the plan but was excluded from the final meeting, two people familiar with the decision-making process but not authorized to speak publicly about private deliberations said on condition of anonymity. Other White House officials highlighted the practical limitations of Biden’s decision, but the symbolism won the day.

Trade groups warned it could curtail future investment in lifesaving drugs, and vaccine manufacturers and some Republican lawmakers warned that it would amount to a giveaway of American technological knowhow to China. Vaccine manufacturing historically has not been a huge profit driver for drug makers.

“The Chinese Communist Party is already celebrating this gift from President Biden,” tweeted Arkansas Sen. Tom Cotton, as he highlighted a comment from a Chinese official praising Biden’s action.

A vaccine manufactured by a Chinese company was given emergency-use authorization Friday by the World Health Organization , potentially creating a pathway for millions of the doses to reach needy countries through a U.N.-backed program rolling out coronavirus vaccines.

The decision by a WHO technical advisory group — a first for a Chinese vaccine — opens the possibility that Sinopharm’s offering could be included in the U.N.-backed COVAX program in coming weeks or months and distributed through UNICEF and the WHO’s Americas regional office.

But U.S. vaccine manufacturers also warned that the Biden administration’s move could hurt the global supply of shots in the near to medium term.

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 39.61
+0.19 +0.48%
Volume: 15.98M
June 22, 2021 4:02p
P/E Ratio
20.15
Dividend Yield
3.94%
Market Cap
$220.66 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 236.49
+10.40 +4.60%
Volume: 2.03M
June 22, 2021 4:00p
P/E Ratio
41.84
Dividend Yield
N/A
Market Cap
$54.61 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/222361179/delayed
XE : Germany: Xetra
195.80
+7.40 +3.93%
Volume: 154,205
June 22, 2021 6:30p
P/E Ratio
42.11
Dividend Yield
N/A
Market Cap
€45.84 billion
Rev. per Employee
€248,493
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 221.36
+13.12 +6.30%
Volume: 10.07M
June 22, 2021 4:00p
P/E Ratio
176.52
Dividend Yield
N/A
Market Cap
$83.61 billion
Rev. per Employee
$617,996
loading...
1 2
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.